Published in
Elsevier, European Journal of Cancer, (115), p. 24-26, 2019
DOI: 10.1016/j.ejca.2019.04.011
Links
Tools
Comment on ‘Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer’—No support for de-escalation of immunotherapy
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 